Journal
PHARMACEUTICALS
Volume 15, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/ph15010028
Keywords
baloxavir marboxil; influenza; baloxavir acid; prodrug; cap-dependent endonuclease; Xofluza
Categories
Ask authors/readers for more resources
Baloxavir marboxil is a new drug developed in Japan that treats seasonal flu and has been marketed in multiple countries. It is effective against both influenza A and B viruses, although the B strain is more resistant. The drug is currently undergoing post-marketing surveillance and may be used for treating COVID-19.
Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available